2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Insertion of a
microaxial flow pump (Impella) to prevent death in in cardiogenic shock has received a class IIa LOE B-R recommendation. IABP and VA-ECMO are class III for rourine use.
Gregg W. Stone MD
5,322 posts
Interventional cardiologist, trialist, innovator, educator, husband, father, loyal friend
New York and the world
Joined December 2016
- Our perspective on the vulnerable plaque and vulnerable patient just published in Nature Reviews Cardiology. Please DM me a request with your email address and I would be pleased to send you a journal-approved copy.
- Published today in EHJ: Meta-analysis of all left main DES vs. CABG RCTs. 5 trials, 4612 pts, mean 5.6 year follow-up (including all long-term data from EXCEL, NOBLE and SYNTAX). Similar all-cause rates of death with PCI and CABG - RR 1.03, 95% CI 0.81–1.32; P = 0.78.
- #EXCEL investigators detailed response to the false narrative that has been promulgated. tctmd.com/slide/official… Please read and move beyond sensationalism, back to science and patient care. Note: We will not further debate this in the press or on Twitter.
- MitraClip approved by FDA today for Rx of severe secondary MR in pts with heart failure who remain symptomatic despite GDMT. Great day for suffering pts in whom this therapy offers potential for improved survival, reduced hospitalizations and enhanced quality-of-life.
- MASTER DAPT trial. Important because this is the first trial in a high bleeding risk population adequately sized to convincingly demonstrate non-inferiority for ischemia. The new standard of care.
- ISCHEMIA cost $100M of taxpayer money. Some are complaining that’s outrageous. Is it? There are 140,000,000 US taxpayers. ISCHEMIA took 7 years. That’s 10 cents per taxpayer per year. Worth it? I think so!! We should fund more major trials like this addressing essential issues.
- NEW! 2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Intravascular imaging guidance with OCT or IVUS during PCI in ACS is now recommended for left main or complex lesions with a class IA recommendation.
- At the Mount Sinai Hospital system, we’ve been running ~2000 COVID-19 in-pts per day, with ~500 in ICUs. Finally starting to see a downturn in these numbers. More than 2800 patients have been discharged. Amazing effort by everyone on the front line as well as hospital leadership.#COVID19 #COVID19nyc 3 days make a trend? After the incredible bravery & sacrifices of @MountSinaiNYC staff, we finally see 3 consecutive days of fewer #Covid_19 cases @MountSinaiNYC. Lockdowns work. @IcahnMountSinai
- Both PARTNER 3 and EVOLUT low risk trials show reduced composite death/stroke/rehosp in low risk AS pts. Much faster recovery and early QOL. Some diffs between the trials in PPM, PV leaks, valve hemodynamics, but results both overwhelmingly positive. A new era has begun.
- FDA has approved the pivotal randomized trial of Impella in 668 pts with anterior STEMI designed to demonstrate that LV unloading starting pre-PCI will safely reduce Infarct size. Hugely important study.
- IVUS used in only 5.6% of nearly 2 million Medicare PCI pts - but strongly associated with reduced death, MI and reintervention (JACC CV Int publ today). Similar results to 10 RCTs. So why isn't IVUS (or OCT) used more frequently? Poll to follow.
- Amazing case in JACC Int of a 58 yo asymptomatic man who developed a STEMI from plaque rupture 2 hrs after a routine CT with 0 calcium. It's the plaque morphology and inflammation, not the calcium that predicts risk! Calcium is a marker useful in some but (obviously) not all pts.
- The EXCEL, NOBLE, SYNTAX and PRECOMBAT investigators have agreed to pool the data from their trials for an independently led individual patient data pooled analysis. Hopefully the data analysis will be completed and reported later this year.














